The Impact of the COVID-19 Pandemic on the Antibiotic Resistance of Gram-Negative Pathogens Causing Bloodstream Infections in an Intensive Care Unit.

Andreea Loredana Golli, Simona Georgiana Popa, Alice Elena Ghenea, Flavia Liliana Turcu
Author Information
  1. Andreea Loredana Golli: Department of Public Health and Management, University of Medicine & Pharmacy Craiova, 200349 Craiova, Romania. ORCID
  2. Simona Georgiana Popa: Department of Diabetes, Nutrition and Metabolic Diseases, University of Medicine & Pharmacy Craiova, 200349 Craiova, Romania.
  3. Alice Elena Ghenea: Department of Bacteriol Virol Parasitol, University of Medicine & Pharmacy Craiova, 200349 Craiova, Romania.
  4. Flavia Liliana Turcu: Department of Nephrol & Dialysis, Carol Davila University of Medicine & Pharmacy Bucharest, 050474 Bucharest, Romania.

Abstract

: In this research, we aimed to analyze the trend of the antimicrobial resistance pattern of Gram-negative isolated in blood samples collected from patients with severe invasive infections hospitalized in the intensive care unit in selected periods during and after COVID-19. : A retrospective study of bacterial pathogens was performed on 481 patients admitted to the ICU between 2020 and 2023. The resistance patterns were analyzed using the Vitek 2 Compact system. . A total of 686 Gram-negative bacterial isolates were obtained. The most frequently detected Gram-negative pathogens were spp. (30.91%), spp. (24.64%), and (18.95%). Almost 50% of all the pathogens were multidrug-resistant, with a statistically significant increase post-pandemic ( < 0.05). Post-pandemic, the study highlighted a significantly higher percentage of the strains ( < 0.05), and a significant increase in the antibiotic resistance rate against colistin ( < 0.001) and tigecycline ( = 0.005). A very high percentage of MDR Acinetobacter spp. isolates was found, with a significant increase in the antibiotic resistance rate against colistin ( < 0.001). A significantly lower resistance was recorded for the strains in the case of ceftazidime ( = 0.03) and aminoglycosides (gentamicin- = 0.01, amikacin- < 0.001). An increase in the percentage of carbapenem-resistant spp., spp., and spp. strains was observed, and a significant decrease in the in the case of spp. ( = 0.01). : Our findings revealed a statistically significant increase in the resistance rate to last-line antibiotics and in the percentage of MDR Gram-negative strains isolated in the blood samples in the post-COVID-19 era.

Keywords

References

  1. Antibiotics (Basel). 2021 Jul 16;10(7): [PMID: 34356789]
  2. J Clin Diagn Res. 2017 Feb;11(2):DC01-DC07 [PMID: 28384858]
  3. Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55 [PMID: 24329732]
  4. Clin Microbiol Infect. 2012 Mar;18(3):268-81 [PMID: 21793988]
  5. Rom J Morphol Embryol. 2012;53(3 Suppl):835-40 [PMID: 23188450]
  6. Pathogens. 2022 Oct 28;11(11): [PMID: 36365001]
  7. Intensive Care Med. 2020 Feb;46(2):266-284 [PMID: 32047941]
  8. Antibiotics (Basel). 2024 Jan 26;13(2): [PMID: 38391509]
  9. Antibiotics (Basel). 2023 Nov 03;12(11): [PMID: 37998792]
  10. Exp Ther Med. 2018 Dec;16(6):4499-4510 [PMID: 30542398]
  11. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468 [PMID: 32358954]
  12. Rev Panam Salud Publica. 2023 Apr 19;47:e10 [PMID: 37082532]
  13. Antibiotics (Basel). 2020 Sep 22;9(9): [PMID: 32971809]
  14. Nat Rev Microbiol. 2024 Oct 17;: [PMID: 39420097]
  15. Health Sci Rep. 2023 Mar 15;6(3):e1153 [PMID: 36938144]
  16. J Infect Public Health. 2023 Apr;16(4):611-617 [PMID: 36857834]
  17. Intensive Care Med. 2023 Feb;49(2):178-190 [PMID: 36764959]
  18. Infect Drug Resist. 2024 Nov 19;17:5087-5096 [PMID: 39584180]
  19. Antibiotics (Basel). 2024 Feb 23;13(3): [PMID: 38534649]
  20. Antibiotics (Basel). 2024 Mar 31;13(4): [PMID: 38666996]
  21. Antibiotics (Basel). 2023 May 26;12(6): [PMID: 37370285]
  22. Pathogens. 2023 May 30;12(6): [PMID: 37375470]
  23. Virulence. 2016 Apr 2;7(3):248-51 [PMID: 26890622]
  24. Lancet Glob Health. 2018 Jun;6(6):e619-e629 [PMID: 29681513]
  25. Sci Rep. 2021 Aug 19;11(1):16876 [PMID: 34413340]
  26. Pharmaceuticals (Basel). 2024 Mar 22;17(4): [PMID: 38675369]
  27. Int J Mol Sci. 2023 Apr 26;24(9): [PMID: 37175597]
  28. J Infect. 2024 Oct;89(4):106256 [PMID: 39216832]
  29. Curr Opin Infect Dis. 2019 Dec;32(6):609-616 [PMID: 31567571]
  30. Antibiotics (Basel). 2023 Jan 27;12(2): [PMID: 36830166]

Word Cloud

Created with Highcharts 10.0.00resistancesppGram-negativesignificantincrease<pathogenspercentagestrains=:COVID-19rate001antimicrobialisolatedbloodsamplespatientsinfectionsstudybacterialisolatesstatistically05significantlyantibioticcolistinMDRcase01researchaimedanalyzetrendpatterncollectedsevereinvasivehospitalizedintensivecareunitselectedperiodsretrospectiveperformed481admittedICU20202023patternsanalyzedusingVitek2Compactsystemtotal686obtainedfrequentlydetected3091%2464%1895%Almost50%multidrug-resistantpost-pandemicPost-pandemichighlightedhighertigecycline005highAcinetobacterfoundlowerrecordedceftazidime03aminoglycosidesgentamicin-amikacin-carbapenem-resistantobserveddecreasefindingsrevealedlast-lineantibioticspost-COVID-19eraImpactPandemicAntibioticResistanceGram-NegativePathogensCausingBloodstreamInfectionsIntensiveCareUnitbloodstream

Similar Articles

Cited By